Xadago® (safinamide)
Parkinson's Disease (add-on to levodopa)
ApprovedMarketed
Key Facts
Indication
Parkinson's Disease (add-on to levodopa)
Phase
Approved
Status
Marketed
Company
About Newron Pharmaceuticals
Newron Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing new treatments for patients with diseases of the central and peripheral nervous system. Its key achievement is the development and approval of Xadago® (safinamide), a once-daily oral add-on therapy for Parkinson's disease patients experiencing motor fluctuations. The company's strategy focuses on leveraging its expertise in neurology to advance a pipeline of novel compounds for rare and underserved neurological conditions, including Rett syndrome and other rare epilepsies.
View full company profile